{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:18:06Z","timestamp":1793902686637,"version":"4.8.0"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health","award":["AZV 16-31586A"],"award-info":[{"award-number":["AZV 16-31586A"]}]},{"name":"Ministry of Health","award":["GA\u010cR 20-22102S"],"award-info":[{"award-number":["GA\u010cR 20-22102S"]}]},{"name":"Ministry of Health","award":["PROGRES Q26, Q28, UNCE\/MED\/016"],"award-info":[{"award-number":["PROGRES Q26, Q28, UNCE\/MED\/016"]}]},{"name":"Ministry of Health","award":["GAUK 120119"],"award-info":[{"award-number":["GAUK 120119"]}]},{"name":"Ministry of Health","award":["CZ.1.05\/1.1.00\/02.0109"],"award-info":[{"award-number":["CZ.1.05\/1.1.00\/02.0109"]}]},{"name":"Charles University","award":["AZV 16-31586A"],"award-info":[{"award-number":["AZV 16-31586A"]}]},{"name":"Charles University","award":["GA\u010cR 20-22102S"],"award-info":[{"award-number":["GA\u010cR 20-22102S"]}]},{"name":"Charles University","award":["PROGRES Q26, Q28, UNCE\/MED\/016"],"award-info":[{"award-number":["PROGRES Q26, Q28, UNCE\/MED\/016"]}]},{"name":"Charles University","award":["GAUK 120119"],"award-info":[{"award-number":["GAUK 120119"]}]},{"name":"Charles University","award":["CZ.1.05\/1.1.00\/02.0109"],"award-info":[{"award-number":["CZ.1.05\/1.1.00\/02.0109"]}]},{"name":"ERDF","award":["AZV 16-31586A"],"award-info":[{"award-number":["AZV 16-31586A"]}]},{"name":"ERDF","award":["GA\u010cR 20-22102S"],"award-info":[{"award-number":["GA\u010cR 20-22102S"]}]},{"name":"ERDF","award":["PROGRES Q26, Q28, UNCE\/MED\/016"],"award-info":[{"award-number":["PROGRES Q26, Q28, UNCE\/MED\/016"]}]},{"name":"ERDF","award":["GAUK 120119"],"award-info":[{"award-number":["GAUK 120119"]}]},{"name":"ERDF","award":["CZ.1.05\/1.1.00\/02.0109"],"award-info":[{"award-number":["CZ.1.05\/1.1.00\/02.0109"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Lymphoma with secondary central nervous system (CNS) involvement represents one of the most aggressive malignancies, with poor prognosis and high mortality. New diagnostic tools for its early detection, response evaluation, and CNS relapse prediction are needed. We analyzed circulating microRNAs in the cerebrospinal fluid (CSF) and plasma of 162 patients with aggressive B-cell non-Hodgkin\u2019s lymphomas (B-NHL) and compared their levels in CNS-involving lymphomas versus in systemic lymphomas, at diagnosis and during treatment and CNS relapse. We identified a set of five oncogenic microRNAs (miR-19a, miR-20a, miR-21, miR-92a, and miR-155) in CSF that detect, with high sensitivity, secondary CNS lymphoma involvement in aggressive B-NHL, including DLBCL, MCL, and Burkitt lymphoma. Their combination into an oncomiR index enables the separation of CNS lymphomas from systemic lymphomas or nonmalignant controls with high sensitivity and specificity, and high Receiver Operating Characteristics (DLBCL AUC = 0.96, MCL = 0.93, BL = 1.0). Longitudinal analysis showed that oncomiR levels reflect treatment efficacy and clinical outcomes, allowing their monitoring and prediction. In contrast to conventional methods, CSF oncomiRs enable detection of early and residual CNS involvement, as well as parenchymal involvement. These circulating oncomiRs increase 1\u20134 months before CNS relapse, allowing its early detection and improving the prediction of CNS relapse risk in DLBCL. Similar effects were detectable, to a lesser extent, in plasma.<\/jats:p>","DOI":"10.3390\/cancers14092305","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T14:49:38Z","timestamp":1651848578000},"page":"2305","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-4282","authenticated-orcid":false,"given":"Pavle","family":"Krsmanovic","sequence":"first","affiliation":[{"name":"Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Mocikova","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, 100 34 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Chramostova","sequence":"additional","affiliation":[{"name":"Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Klanova","sequence":"additional","affiliation":[{"name":"Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"},{"name":"1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Trnkova","sequence":"additional","affiliation":[{"name":"1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-0797","authenticated-orcid":false,"given":"Michal","family":"Pesta","sequence":"additional","affiliation":[{"name":"Faculty of Mathematics and Physics, Charles University, 186 75 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Laslo","sequence":"additional","affiliation":[{"name":"Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, St James\u2019s University Hospital, University of Leeds, Leeds LS2 9JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pytlik","sequence":"additional","affiliation":[{"name":"Department of Cell Therapy, Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Stopka","sequence":"additional","affiliation":[{"name":"1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic"},{"name":"Biocev, 1st Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit","family":"Pospisil","sequence":"additional","affiliation":[{"name":"Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hon.881","article-title":"Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: Incidence, risk factors and therapeutic options","volume":"27","author":"Ferreri","year":"2009","journal-title":"Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","volume":"93","author":"Cheah","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin\u2019s lymphoma: A risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: Clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2005.05703.x","article-title":"Central nervous system-directed preventative therapy in adults with lymphoma","volume":"131","author":"McMillan","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","article-title":"A systematic approach to the diagnosis of suspected central nervous system lymphoma","volume":"70","author":"Scott","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/leu.2011.169","article-title":"Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma","volume":"25","author":"Deckert","year":"2011","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","article-title":"Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL","volume":"133","author":"Klanova","year":"2019","journal-title":"Blood"},{"key":"ref_9","first-page":"613","article-title":"Complications of MRI-guided stereotactic biopsy of brain lymphoma","volume":"35","author":"Malikova","year":"2014","journal-title":"Neuroendocrinol. Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00277-016-2744-5","article-title":"Central nervous system relapse in patients with diffuse large B cell lymphoma: Analysis of the risk factors and proposal of a new prognostic model","volume":"95","author":"Kanemasa","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","article-title":"Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL","volume":"127","author":"Savage","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.13276","article-title":"A clinician\u2019s guide to double hit lymphomas","volume":"168","author":"Cheah","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1101\/gr.098046.109","article-title":"Reprogramming of miRNA networks in cancer and leukemia","volume":"20","author":"Volinia","year":"2010","journal-title":"Genome Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1373\/clinchem.2010.147405","article-title":"The microRNA spectrum in 12 body fluids","volume":"56","author":"Weber","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejca.2014.10.028","article-title":"Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients","volume":"51","author":"Roth","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2018.05.006","article-title":"Over expression of circulating miR-155 predicts prognosis in diffuse large B-cell lymphoma","volume":"70","author":"Ahmadvand","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","article-title":"Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system","volume":"117","author":"Baraniskin","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-012-0908-2","article-title":"Micrornas in Cerebrospinal Fluid as Biomarker for Disease Course Monitoring in Primary Central Nervous System Lymphoma","volume":"109","author":"Baraniskin","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zajdel, M., Rymkiewicz, G., Sromek, M., Cieslikowska, M., Swoboda, P., Kulinczak, M., Goryca, K., Bystydzienski, Z., Blachnio, K., and Ostrowska, B. (2019). Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. Cancers, 11.","DOI":"10.3390\/cancers11111647"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kopkova, A., Sana, J., Machackova, T., Vecera, M., Radova, L., Trachtova, K., Vybihal, V., Smrcka, M., Kazda, T., and Slaby, O. (2019). Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors. Cancers, 11.","DOI":"10.3390\/cancers11101546"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12974-019-1590-5","article-title":"Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a\/b in patients with multiple sclerosis and active lesions","volume":"16","author":"Reverter","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/01616412.2016.1250857","article-title":"Identification of the miRNA-mRNA regulatory network in multiple sclerosis","volume":"39","author":"Yang","year":"2017","journal-title":"Neurol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sochor, M., Basova, P., Pesta, M., Dusilkova, N., Bartos, J., Burda, P., Pospisil, V., and Stopka, T. (2014). Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-448"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-03-3773","article-title":"Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma","volume":"64","author":"Ota","year":"2004","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nature03552","article-title":"A microRNA polycistron as a potential human oncogene","volume":"435","author":"He","year":"2005","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1101\/gad.1861409","article-title":"miR-19 is a key oncogenic component of mir-17-92","volume":"23","author":"Olive","year":"2009","journal-title":"Genes Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.0500613102","article-title":"Accumulation of miR-155 and BIC RNA in human B cell lymphomas","volume":"102","author":"Eis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/path.1825","article-title":"BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas","volume":"207","author":"Kluiver","year":"2005","journal-title":"J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ijc.22800","article-title":"MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma","volume":"121","author":"Lawrie","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2141.2008.07237.x","article-title":"MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas","volume":"142","author":"Roehle","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/gcc.10316","article-title":"High expression of precursor microRNA-155\/BIC RNA in children with Burkitt lymphoma","volume":"39","author":"Metzler","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_36","first-page":"89","article-title":"MicroRNA-21 and microRNA-155 promote the progression of Burkitt\u2019s lymphoma by the PI3K\/AKT signaling pathway","volume":"13","author":"Han","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12185-015-1847-4","article-title":"Oncogenic microRNA-155 and its target PU.1: An integrative gene expression study in six of the most prevalent lymphomas","volume":"102","author":"Huskova","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ni1575","article-title":"Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes","volume":"9","author":"Xiao","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"18208","DOI":"10.1073\/pnas.1315365110","article-title":"B-cell malignancies in microRNA Emu-miR-17~92 transgenic mice","volume":"110","author":"Sandhu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1038\/emboj.2011.317","article-title":"Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation","volume":"30","author":"Pospisil","year":"2011","journal-title":"The EMBO J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2011-02-335141","article-title":"Macrophage development from HSCs requires PU.1-coordinated microRNA expression","volume":"118","author":"Ghani","year":"2011","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:06:49Z","timestamp":1760137609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092305"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092305","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]}}}